139 related articles for article (PubMed ID: 35108650)
1. Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vλ6 proteins associated with AL amyloidosis.
Takahashi D; Matsunaga E; Yamashita T; Caaveiro JMM; Abe Y; Ueda T
Biochem Biophys Res Commun; 2022 Mar; 596():22-28. PubMed ID: 35108650
[TBL] [Abstract][Full Text] [Related]
2. Effect of O-glycosylation on amyloid fibril formation of the variable domain in the Vλ6 light chain mutant Wil.
Abe Y; Shibata H; Oyama K; Ueda T
Int J Biol Macromol; 2021 Jan; 166():342-351. PubMed ID: 33127550
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of amyloid fibril formation in the variable domain of λ6 light chain mutant Wil caused by the interaction between its unfolded state and epigallocatechin-3-O-gallate.
Abe Y; Odawara N; Aeimhirunkailas N; Shibata H; Fujisaki N; Tachibana H; Ueda T
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2570-2578. PubMed ID: 30251653
[TBL] [Abstract][Full Text] [Related]
4. Residual structures in the acid-unfolded states of Vlambda6 proteins affect amyloid fibrillation.
Mishima T; Ohkuri T; Monji A; Kanemaru T; Abe Y; Ueda T
J Mol Biol; 2009 Oct; 392(4):1033-43. PubMed ID: 19647748
[TBL] [Abstract][Full Text] [Related]
5. Mutational and genetic determinants of λ6 light chain amyloidogenesis.
González-Andrade M; Becerril-Luján B; Sánchez-López R; Ceceña-Álvarez H; Pérez-Carreón JI; Ortiz E; Fernández-Velasco DA; del Pozo-Yauner L
FEBS J; 2013 Dec; 280(23):6173-83. PubMed ID: 24107228
[TBL] [Abstract][Full Text] [Related]
6. A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis.
Hernández-Santoyo A; del Pozo Yauner L; Fuentes-Silva D; Ortiz E; Rudiño-Piñera E; Sánchez-López R; Horjales E; Becerril B; Rodríguez-Romero A
J Mol Biol; 2010 Feb; 396(2):280-92. PubMed ID: 19941869
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Light Chain 6aJL2-R24G Amyloid Fiber Formation Associated with Light Chain Amyloidosis.
Pelaez-Aguilar AE; Rivillas-Acevedo L; French-Pacheco L; Valdes-Garcia G; Maya-Martinez R; Pastor N; Amero C
Biochemistry; 2015 Aug; 54(32):4978-86. PubMed ID: 26214579
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structure of a light chain-derived amyloid fibril from a patient with systemic AL amyloidosis.
Radamaker L; Lin YH; Annamalai K; Huhn S; Hegenbart U; Schönland SO; Fritz G; Schmidt M; Fändrich M
Nat Commun; 2019 Mar; 10(1):1103. PubMed ID: 30894526
[TBL] [Abstract][Full Text] [Related]
9. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity.
Wall J; Schell M; Murphy C; Hrncic R; Stevens FJ; Solomon A
Biochemistry; 1999 Oct; 38(42):14101-8. PubMed ID: 10529258
[TBL] [Abstract][Full Text] [Related]
10. A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ6 Light Chain Promotes Pathologic Amyloid Formation.
Peterle D; Klimtchuk ES; Wales TE; Georgescauld F; Connors LH; Engen JR; Gursky O
J Mol Biol; 2021 Dec; 433(24):167310. PubMed ID: 34678302
[TBL] [Abstract][Full Text] [Related]
11. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
[TBL] [Abstract][Full Text] [Related]
12. Identification of clonal immunoglobulin λ light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.
Kimura K; Tsukamoto S; Miyazaki K; Kawajiri-Manako C; Ishii A; Rahmutulla B; Fukuyo M; Oshima-Hasegawa N; Mitsukawa S; Takeda Y; Mimura N; Takeuchi M; Ohwada C; Iseki T; Matsusaka K; Sanada M; Yokote K; Kaneda A; Ishida T; Suzuki K; Nakaseko C; Sakaida E
Exp Hematol; 2021 Sep; 101-102():34-41.e4. PubMed ID: 34411686
[TBL] [Abstract][Full Text] [Related]
13. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
[TBL] [Abstract][Full Text] [Related]
14. Probing the role of λ6 immunoglobulin light chain dimerization in amyloid formation.
Wolwertz ML; Nguyen PT; Quittot N; Bourgault S
Biochim Biophys Acta; 2016 Apr; 1864(4):409-18. PubMed ID: 26802902
[TBL] [Abstract][Full Text] [Related]
15. Structure and energetic basis of overrepresented λ light chain in systemic light chain amyloidosis patients.
Zhao J; Zhang B; Zhu J; Nussinov R; Ma B
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2294-2303. PubMed ID: 29241665
[TBL] [Abstract][Full Text] [Related]
16. Mechanism for retardation of amyloid fibril formation by sugars in Vλ6 protein.
Abe M; Abe Y; Ohkuri T; Mishima T; Monji A; Kanba S; Ueda T
Protein Sci; 2013 Apr; 22(4):467-74. PubMed ID: 23389799
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of amyloidogenic mutations in hypervariable regions of antibody light chains.
Rottenaicher GJ; Weber B; Rührnößl F; Kazman P; Absmeier RM; Hitzenberger M; Zacharias M; Buchner J
J Biol Chem; 2021; 296():100334. PubMed ID: 33508322
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
19. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
Bhutani D; Leng S; Lentzsch S
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins.
Wall JS; Gupta V; Wilkerson M; Schell M; Loris R; Adams P; Solomon A; Stevens F; Dealwis C
J Mol Recognit; 2004; 17(4):323-31. PubMed ID: 15227639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
